The J. M. Smucker Company
—- Market cap
- $12.94B
- Debt
- +$6.96B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 65% equity / 35% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SJM stock price vs OMI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OMI's multiple
Needs OMI P/S.
Implied fair value · at SJM's multiple
Needs Revenue / share.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 65% equity / 35% debt
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The J. M. Smucker Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Accendra Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SJM can materially improve margins and reduce leverage faster than the current 3.7% growth and 6.4% EBITDA margin imply, then hold or selectively own it; otherwise, the large gap between the $116.31 price and the $9.41 to $12.73 DCF range argues for caution because valuation is not well supported by the provided fundamentals.
SJM trades at 1.4x P/S and 33.0x EV/EBITDA, which is a demanding multiple set against only 3.7% revenue growth and negative net income. OMI is not directly comparable on valuation because key multiples are unavailable, but its operating profile is much weaker, so the main issue for SJM is not OMI discount but absolute valuation versus its own fundamentals and model-based range.
Supporting Metrics